1-17 of 17
Edwin Clark
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 1150: Targeting MET Exon 14 mutations with the selective small molecule inhibitor Savolitinib

Evan Barry, Elizabeth Maloney, Ryan Henry, Alexandra Borodovsky, Edwin Clark, Melanie Frigault, Michael Zinda, Celina D’Cruz
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 1150.
https://doi.org/10.1158/1538-7445.AM2016-1150
Published: 15 July 2016
View article titled, Abstract 1150: Targeting MET Exon 14 mutations with the selective small molecule inhibitor Savolitinib
Journal Articles

Abstract 1971: BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer

Garrett W. Rhyasen, Yi Yao, Austin Dulak, Lillian Castriotta, Kelly Jacques, Maureen Hattersley, Gordon B. Mills, Michael Zinda, Stephen Fawell, Paul Lyne, Edwin Clark, Huawei Chen
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 1971.
https://doi.org/10.1158/1538-7445.AM2016-1971
Published: 15 July 2016
View article titled, Abstract 1971: BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer
Journal Articles

Abstract 1477: Pharmacodynamic response and anti-tumor activity of the MET inhibitor AZD6094 in papillary renal cell carcinoma patient derived xenograft models

Alwin Schuller, Evan Barry, Rhys Jones, Melanie Frigault, Garry Beran, Ryan Henry, David Linsenmayer, Maureen Hattersley, Aaron Smith, Joanne Wilson, Ammar Adam, Michael Zinda, Corinne Reimer, Stephen Fawell, Edwin Clark, Celina D'Cruz
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 1477.
https://doi.org/10.1158/1538-7445.AM2015-1477
Published: 01 August 2015
View article titled, Abstract 1477: Pharmacodynamic response and anti-tumor activity of the MET inhibitor AZD6094 in papillary renal cell carcinoma patient derived xenograft models
Journal Articles

Abstract 3114: Targeting MET in preclinical models to support the clinical development of Volitinib in NSCLC

Celina D'Cruz, Melanie Frigault, Ammar Adam, Minhui Shen, Garry Beran, Evan Barry, Paul Gavine, Yongxin Ren, Shiming Fan, Feng Zhou, Weiguo Qing, Mike Zinda, Weiguo Su, Edwin Clark
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 3114.
https://doi.org/10.1158/1538-7445.AM2014-3114
Published: 01 October 2014
View article titled, Abstract 3114: Targeting MET in preclinical models to support the clinical development of Volitinib in NSCLC
Journal Articles

Abstract 3571: Exploratory biomarker discovery for clinical development of ARQ 087, a potent pan-FGFR kinase inhibitor

Yi Yu, Xiubin Gu, Enkelada Nakuci, Xiaolan Zhao, Edward Chang, Jeff Szwaya, Jenn Castro, Laura Cousens, Cathy Bull, Yunxia Wang, Ron Savage, Carol Waghorne, Chang-Rung Chen, Dennis S. France, Edwin Clark, Thomas C.K. Chan
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 3571.
https://doi.org/10.1158/1538-7445.AM2011-3571
Published: 15 April 2011
View article titled, Abstract 3571: Exploratory biomarker discovery for clinical development of ARQ 087, a potent pan-FGFR kinase inhibitor
Journal Articles

Abstract 3478: PI3K suppression by the mTOR inhibitor ridaforolimus and the AKT inhibitor MK-2206 is associated with enhanced anti-tumor activity and hyperglycemia in preclinical models

Marlene C. Artime, Samuel Blackman, Scot Ebbinghaus, Ray Lee, Alessandra Di Bacco, Diana Gargano, Theresa Zhang, Nagaraja Muniappa, Punam Sandhu, Gail Gitzlaff, Cynthia Chavez-Eng, James Watters, Melissa Chenard, Edwin Clark, Christopher Winter, Brian B. Haines
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 3478.
https://doi.org/10.1158/1538-7445.AM10-3478
Published: 15 April 2010
View article titled, Abstract 3478: PI3K suppression by the mTOR inhibitor ridaforolimus and the AKT inhibitor MK-2206 is associated with enhanced anti-tumor activity and hyperglycemia in preclinical models
Journal Articles

Abstract LB-284: Combination of antiandrogens and PI3-kinase pathway inhibitors in a model of androgen-dependent prostate cancer

Clay Efferson, Joe Zhu, Chris Ware, Jennifer Tammam, Minilik Angagaw, John F. Reilly, Cyrille Sur, Edwin Clark, Chris Winter, Weisheng Zhang, Pradip K. Majumder
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): LB-284.
https://doi.org/10.1158/1538-7445.AM10-LB-284
Published: 15 April 2010
View article titled, Abstract LB-284: Combination of antiandrogens and PI3-kinase pathway inhibitors in a model of androgen-dependent prostate cancer
Journal Articles

The Mechanisms of Differential Sensitivity to an Insulin-like Growth Factor-1 Receptor Inhibitor (BMS-536924) and Rationale for Combining with EGFR/HER2 Inhibitors

Fei Huang, Ann Greer, Warren Hurlburt, Xia Han, Rameh Hafezi, Gayle M. Wittenberg, Karen Reeves, Jiwen Chen, Douglas Robinson, Aixin Li, Francis Y. Lee, Marco M. Gottardis, Edwin Clark, Lee Helman, Ricardo M. Attar, Ashok Dongre, Joan M. Carboni
Journal: Cancer Research
Cancer Res (2009) 69 (1): 161–170.
https://doi.org/10.1158/0008-5472.CAN-08-0835
Published: 31 December 2008
View article titled, The Mechanisms of Differential Sensitivity to an Insulin-like Growth Factor-1 Receptor Inhibitor (BMS-536924) and Rationale for Combining with EGFR/HER2 Inhibitors
Open the PDF for The Mechanisms of Differential Sensitivity to an Insulin-like Growth Factor-1 Receptor Inhibitor (BMS-536924) and Rationale for Combining with EGFR/HER2 Inhibitors in another window
Includes: Supplementary data
Journal Articles

Incorporating tissue-based predictive biomarkers in oncology clinical trials .

Edwin Clark
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): SY20-03.
Published: 01 May 2008
View article titled, Incorporating tissue-based predictive biomarkers in oncology clinical trials .
Journal Articles

Effects of brivanib alaninate on FGF2-induced proliferation in human cancer cell lines

Mark Ayers, Suganthy Yoganathan, Xia Han, Shujian Wu, Vishal Patel, Aiqing He, Edwin Clark, Joseph Fargnoli
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 3321.
Published: 01 May 2008
View article titled, Effects of brivanib alaninate on FGF2-induced proliferation in human cancer cell lines
Journal Articles

Expression of epiregulin and amphiregulin and K-RAS mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab (Erbitux     ®)

Shirin Khambata Ford, Christopher Garrett, Edwin Clark, Mark Basik, Christopher Harbison, Tai Wong, Xin Huang, Shujian Wu, Chris Takimoto, Andrew Godwin, Manuel Hidalgo, Jose Baselga, Neal Meropol, David Mauro
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 5670.
Published: 01 May 2007
View article titled, Expression of epiregulin and amphiregulin and <em>K-RAS</em> mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab (Erbitux     <sup>®</sup>)
Journal Articles

Comparison of a dual inhibitor of VEGF and FGF signaling, BMS-582664, to the activity of bevacizumab, an inhibitor exclusively of VEGF signaling, in xenograft models of colon carcinoma.

Mark Ayers, Gennaro Dito, Benjamin Henley, Robert Jeyaseelan, Suganthy Yoganthan, Xia Han, Qiuyan Wu, Suso Platero, Shujian Wu, David Feltquate, Edwin Clark, Joseph Fargnoli
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 1618.
Published: 01 May 2007
View article titled, Comparison of a dual inhibitor of VEGF and FGF signaling, BMS-582664, to the activity of bevacizumab, an inhibitor exclusively of VEGF signaling, in xenograft models of colon carcinoma.
Journal Articles

Identification of Candidate Molecular Markers Predicting Sensitivity in Solid Tumors to Dasatinib: Rationale for Patient Selection

Fei Huang, Karen Reeves, Xia Han, Craig Fairchild, Suso Platero, Tai W. Wong, Francis Lee, Peter Shaw, Edwin Clark
Journal: Cancer Research
Cancer Res (2007) 67 (5): 2226–2238.
https://doi.org/10.1158/0008-5472.CAN-06-3633
Published: 01 March 2007
View article titled, Identification of Candidate Molecular Markers Predicting Sensitivity in Solid Tumors to Dasatinib: Rationale for Patient Selection
Open the PDF for Identification of Candidate Molecular Markers Predicting Sensitivity in Solid Tumors to Dasatinib: Rationale for Patient Selection in another window
Includes: Supplementary data
Journal Articles

Effects of oncogenic NRAS suppression on gene expression in human melanoma cell lines.

Malihe Eskandarpour, Fei Haung, Karen A. Revees, Edwin Clark, Johan Hansson
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 1178.
Published: 15 April 2006
View article titled, Effects of oncogenic NRAS suppression on gene expression in human melanoma cell lines.
Journal Articles

Protein profiling approaches to identify predictive markers of tumor response to Cetuximab (Erbitux) using xenograft models

Ji Gao, Robert C. Wild, Robert Carney, Keith Ho, Douglas Robinson, Tai W. Wong, Edwin Clark, David Mauro, Ashok R. Dongre
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 730.
Published: 01 May 2005
View article titled, Protein profiling approaches to identify predictive markers of tumor response to Cetuximab (Erbitux) using xenograft models
Journal Articles

Transcriptional characteristics of genomic instabilities for colorectal cancer patients

Xia Han, Edwin Clark, Peter M. Shaw, Ayan Banerjea, Shafi Ahmed, Michael P. Powar, Rebecca E. Hands, Stephen A. Bustin, Sina Dorudi, Fei Huang
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 840.
Published: 01 May 2005
View article titled, Transcriptional characteristics of genomic instabilities for colorectal cancer patients
Journal Articles

Gene expression profiling as a predictor of outcome in colorectal cancer patients

Xia Han, Shafi Ahmed, Michael P. Powar, Ayan Banerjea, Sina Dorudi, Edwin Clark, Peter M. Shaw, Fei Huang
Journal: Cancer Research
Cancer Res (2004) 64 (7_Supplement): 1165.
Published: 01 April 2004
View article titled, Gene expression profiling as a predictor of outcome in colorectal cancer patients